Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses Kreutzer-Limmer RNAi Patents to IDT

NEW YORK, Feb. 28 (GenomeWeb News) - Integrated DNA Technologies has taken a non-exclusive license from Alnylam to provide RNAi research products and services under the Kreutzer-Limmer patent family, Alnylam said today.


The Kreutzer-Limmer patent family, owned exclusively by Alnylam, covers small interfering RNAs and their use to mediate RNAi in mammalian cells.


Alnylam said that the IDT deal brings to 20 the number of license agreements it has executed, including 11 with research product suppliers.


Financial terms of the deal were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.